| 前收市價 | 0.0600 |
| 開市 | 0.0500 |
| 買盤 | 0.0400 |
| 賣出價 | 0.1000 |
| 拍板 | 90.00 |
| 到期日 | 2023-02-17 |
| 今日波幅 | 0.0500 - 0.0500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2.01k |
- Benzinga
Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023
Merck & Co Inc's (NYSE: MRK) Q4 sales reached $13.8 billion, +2% Y/Y, beating the consensus of $13.67 billion. Excluding the foreign exchange impact, revenues were up 8%. Pharmaceutical sales increased by 1% to $12.2 billion. Excluding the unfavorable impact of foreign exchange, pharmaceutical sales grew 9%, primarily driven by oncology and hospital acute care, partially offset by diabetes. Growth in oncology was primarily driven by higher sales of Keytruda, which rose 19% to $5.5 billion. Relat
- Insider Monkey
15 Undervalued Defensive Stocks For 2023
In this article, we will take a look at the 15 undervalued defensive stocks for 2023. You can skip this part and go to 5 Undervalued Defensive Stocks For 2023. Investors flocked to defensive stocks in 2022 amid recession fears and massive losses in the growth stocks space. Defensive stocks are favored by investors during […]
- Insider Monkey
Is Merck & Co. (MRK) a Long-Term Bet?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P […]
